The Gleason score is a grading system used by a pathologist to describe how abnormal prostate cancer cells look under a microscope. The pathologist adds the most common pattern to the highest-grade or second most common pattern, giving scores from 6 to 10 in modern reporting. The Gleason score estimates likely behaviour, not certainty.
Key takeaways
- The Gleason score grades prostate cancer tissue appearance; it does not measure tumour size or whether cancer has spread.
- Modern pathology reports Gleason scores from 6 to 10, alongside Grade Group 1 to 5. Scores of 2 to 5 are no longer assigned to biopsy material.
- A Gleason score exists only when cancer is found. There is no "normal" Gleason score, and a benign biopsy is not "Gleason 0".
- Grading is a trained human judgement and carries genuine observer-to-observer variation; second opinions on slides are common and reasonable.
- The Gleason score is used with PSA, digital rectal examination, MRI and staging scans, never on its own.
At a glance
| Item | Detail |
|---|---|
| What it is | Histological grade of prostate adenocarcinoma |
| Sample source | Prostate needle biopsy, TURP chippings, or removed prostate (radical prostatectomy) |
| Who reports it | Histopathologist, often a uropathologist |
| Scale in current use | Gleason 6 to 10; Grade Group 1 to 5 |
| What it does not tell you | Stage, spread, tumour volume, PSA, genetic risk |
| Typical time to report | Usually a few working days after biopsy; longer if extra stains or a second opinion are needed |
Also known as
- Gleason grade, Gleason sum, Gleason pattern score
- Grade Group (ISUP/WHO Grade Group), often written as "Gleason 3+4=7, Grade Group 2"
- In Indian clinics: "biopsy grading", "prostate biopsy report grade", "prostate cancer grading test"
What the Gleason score is
The Gleason score describes architecture, how prostate gland structures are arranged in the cancerous tissue. Patterns are graded 1 to 5. In current practice, only patterns 3, 4 and 5 are assigned to cancer on biopsy; patterns 1 and 2 are essentially no longer used because those appearances are now recognised as benign mimics or not reproducibly distinguishable.
On a needle biopsy, the pathologist adds the most common pattern plus the highest remaining pattern. On a removed prostate, the most common plus the second most common pattern are added, with any higher-grade minor pattern reported separately as tertiary. This is why the arithmetic matters: Gleason 3+4=7 and 4+3=7 are both "7" but behave differently, with 4+3 generally carrying the higher risk.
Grade Groups
| Gleason score | Grade Group | General meaning |
|---|---|---|
| 3+3 = 6 | Grade Group 1 | Lowest grade pattern seen on biopsy |
| 3+4 = 7 | Grade Group 2 | Favourable intermediate pattern |
| 4+3 = 7 | Grade Group 3 | Unfavourable intermediate pattern |
| 4+4 = 8, 3+5 = 8, 5+3 = 8 | Grade Group 4 | High grade |
| 9 or 10 | Grade Group 5 | Highest grade |
Grade Groups were introduced because "6 out of 10" sounds mid-range to patients when it is in fact the lowest grade reported. Grade Group 1 communicates that more honestly. Ask your urologist to confirm both the Gleason score and the Grade Group on your report.
Why the Gleason score is done
- To describe aggressiveness: grade is one of the strongest available predictors of how prostate cancer is likely to behave.
- To allocate risk category: combined with PSA, clinical stage and the number of positive cores, the grade places the cancer into low, intermediate or high-risk groupings used by treatment guidelines.
- To open or close the door to active surveillance: many men with Grade Group 1 disease are offered monitoring rather than immediate treatment.
- To plan staging: higher grade usually prompts additional imaging to look for spread.
Results vary depending on individual clinical circumstances.
Who gets a Gleason score
A Gleason score is generated only for men who have had prostate tissue sampled and in whom adenocarcinoma is found. Prostate biopsy is typically considered when there is:
- A persistently raised or rising PSA, interpreted with age, prostate size and rate of change
- An abnormal, hard or nodular prostate on digital rectal examination
- A suspicious lesion on multiparametric MRI (commonly PI-RADS 4 or 5, and selected PI-RADS 3 lesions)
- Prostate cancer found incidentally in tissue removed for benign prostatic enlargement
- Rising PSA during surveillance, prompting a repeat or targeted biopsy
Biopsy is not automatic for every raised PSA. Urinary infection, recent catheterisation, prostatitis, recent ejaculation and benign enlargement can all raise PSA. Whether to biopsy is a shared decision that weighs age, other illnesses and life expectancy.
What the Gleason score cannot detect or exclude
- It does not tell you the stage. Grade describes cell appearance only. Whether cancer has reached the capsule, seminal vesicles, lymph nodes or bone comes from examination, MRI, PSMA PET or bone scan.
- It does not measure how much cancer is present. Core length involved and number of positive cores are reported separately and matter.
- A low Gleason score does not exclude higher-grade cancer elsewhere in the prostate. Needle biopsy samples a small fraction of the gland. Upgrading at surgery is well recognised.
- A benign biopsy does not exclude prostate cancer. "No malignancy identified" describes the tissue sampled, not the whole prostate. If PSA continues to rise or symptoms persist despite a normal biopsy, go back to your urologist.
- It does not cover all prostate cancers. Gleason grading applies to acinar adenocarcinoma. Small cell or neuroendocrine prostate cancer is not Gleason graded and behaves differently.
- It does not predict an individual outcome. The Gleason score shifts probabilities; it does not forecast one person's course.
- It does not indicate treatment response or genetic risk. Germline testing, genomic classifiers and imaging answer separate questions.
Related but different examinations
| Test | Question it answers | What it cannot do |
|---|---|---|
| Gleason score / Grade Group | How abnormal do the cancer cells look? | Cannot show location, size or spread |
| PSA blood test | Is there a biochemical signal warranting further assessment? | Not cancer-specific; can be raised by infection or enlargement, and can be normal with cancer present |
| Digital rectal examination | Is the gland irregular or hard posteriorly? | Misses anterior and small tumours |
| Multiparametric MRI (PI-RADS) | Is there a lesion worth targeting on biopsy? | Imaging suspicion is not a grade; MRI cannot give a Gleason score and can miss some cancers, including some high-grade ones |
| TNM stage | How far has the cancer extended? | Says nothing about cell appearance |
| PSMA PET-CT / bone scan | Is there spread beyond the prostate? | Does not grade tissue; false positives and negatives occur |
| Genomic classifier tests | Additional molecular risk information | Limited availability; does not replace grading |
Grade from a needle biopsy and grade from the removed prostate are also distinct. The prostatectomy grade reflects the whole gland and is the more complete assessment; it may be higher or lower than the biopsy grade.
How to prepare
There is no preparation for the Gleason score itself, it is generated in the laboratory. Preparation applies to the biopsy. Protocols differ substantially between hospitals and between transrectal and transperineal approaches. Your unit's written instructions take precedence over anything here.
- Medicines: tell the team about aspirin, clopidogrel, warfarin, apixaban, rivaroxaban, dabigatran and any herbal or AYUSH preparations. Do not stop or alter any prescribed medicine yourself, the prescribing doctor or the urology team will advise.
- Antibiotics: many units give antibiotic prophylaxis, particularly for transrectal biopsy. Regimens vary with local resistance patterns.
- Bowel preparation: some units use an enema before transrectal biopsy; many do not.
- Fasting: required only if sedation or general anaesthesia is planned, which is common for transperineal biopsy.
- Infection check: an active urinary infection is usually treated before biopsy.
- Transport: arrange someone to accompany you if sedation is used.
Men with diabetes on glucose-lowering therapy
If fasting is required, ask the prescriber in advance how to handle insulin or sulfonylureas on the day. Unsupervised fasting on these medicines risks hypoglycaemia.
Men with chronic kidney disease or heart failure
Tell the team before any imaging that may use contrast, and before being asked to drink large volumes of fluid after the procedure. Fluid instructions may need adjusting.
Older adults and men on multiple medicines
Discuss whether biopsy will change management at all. In men with limited life expectancy or significant frailty, the harms may outweigh the information gained.
Men on anticoagulation
Bleeding risk is higher. The decision to pause, bridge or continue anticoagulation is individualised and must come from the treating team.
What happens during the process
The biopsy. Ultrasound guidance is used, often fused with prior MRI images. Local anaesthetic is infiltrated. Multiple cores are taken, usually a systematic set plus targeted cores from any MRI lesion. The sampling itself commonly takes around 10 to 20 minutes; with admission, consent, anaesthesia and recovery, expect to be at the hospital for a few hours. Transperineal biopsy under sedation or anaesthesia takes longer.
The laboratory stage. Cores are fixed, processed into paraffin, sectioned and stained. The pathologist examines each core, identifies cancer, assigns patterns and calculates the score and Grade Group. Immunohistochemistry may be added when the appearance is equivocal, which adds time. Reports are typically ready within a few working days; expert review or referral of slides adds further days.
Understanding your report
A prostate biopsy report usually includes more than the grade. Look for:
- Gleason score written as a sum: for example 3+4=7, plus the Grade Group.
- Number of cores involved out of the total taken, per site.
- Percentage or length of each core involved by cancer.
- Percentage of pattern 4 in Gleason 7 disease, which influences surveillance decisions.
- Perineural invasion, extraprostatic extension or seminal vesicle involvement if seen.
- Cribriform or intraductal carcinoma, both regarded as adverse features.
- Non-cancer findings such as high-grade prostatic intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation (ASAP), which are not cancer but may prompt follow-up.
No report interprets itself. The grade must be read alongside PSA, examination, imaging, your age and your other health conditions by the urologist or uro-oncologist managing your care.
A common misunderstanding about Gleason 6
Many men read "6 out of 10" as moderate. It is the lowest grade reported on biopsy. Grade Group 1 cancers rarely metastasise, and active surveillance is a mainstream, guideline-supported option rather than neglect. Surveillance involves scheduled PSA testing, examination, MRI and repeat biopsy.
When the Gleason score can be misleading
When the grade may be falsely low (undergrading)
- The needle missed the most aggressive focus, a known limitation of sampling a small gland volume.
- Systematic biopsy without MRI targeting, which more often misses anterior tumours.
- Too few cores taken, or cores taken only from one region.
- Small amount of cancer in a core, making pattern assessment harder.
When the grade may be falsely high (overgrading)
- Benign mimics such as adenosis, atrophy or partial atrophy misread as cancer patterns.
- Artefact from crushed or poorly fixed tissue distorting gland architecture.
- Tissue changes after radiotherapy or androgen deprivation therapy, Gleason grading is not considered valid on treated tissue and should be flagged as such.
- Tangential sectioning creating a false impression of fused glands.
Variation between pathologists
Grading is a visual judgement. Agreement between pathologists is good but not complete, particularly at the 3 versus 4 boundary that separates Grade Group 1 from Grade Group 2. That single boundary often decides between surveillance and treatment. A specialist uropathology second opinion before committing to major treatment is a reasonable request and is common practice.
Risks and safety
The Gleason score itself carries no physical risk. The risks belong to the biopsy that produced the tissue, and they differ by approach.
Transrectal ultrasound-guided biopsy
Blood in urine, semen and stool is common and usually settles over days to weeks. Blood in semen can persist for several weeks. The main concern is infection, including urinary infection and sepsis, because the needle passes through the rectal wall. Rising antibiotic resistance has made this a significant consideration in India. Urinary retention can occur.
Transperineal biopsy
The needle passes through perineal skin rather than rectum, and infective complications are generally lower. Bleeding, bruising, perineal pain and urinary retention still occur, and anaesthesia or sedation carries its own risks.
Risks of the information itself
Detecting a low-grade cancer that would never have caused harm can lead to treatment with lasting urinary and sexual side effects. This is why grading and shared decision-making matter as much as the biopsy.
Red flags after a prostate biopsy
Emergency: seek care now
- Fever with shaking chills, feeling very unwell, confusion, rapid breathing, or a racing pulse, possible sepsis
- Complete inability to pass urine with a painful, distended lower abdomen
- Heavy bleeding from the rectum or in urine with clots, dizziness or fainting
Same day: contact your urology team today
- Temperature above normal without other features of sepsis
- Burning on passing urine with increasing frequency and urgency
- Pain that is worsening rather than settling
- Persistent visible blood in urine beyond the timeframe your unit advised
Routine: book an appointment
- Blood in semen persisting for several weeks with no other symptoms
- Mild perineal or rectal soreness that is slowly improving
- Questions about your grade, Grade Group or next steps
Special situations
Older adults
Grade is interpreted against life expectancy and comorbidity. A high grade in a man with a long expected lifespan usually prompts active treatment; the same grade in a man with serious competing illness may be managed with hormonal therapy or observation.
Men on active surveillance
Repeat biopsy or MRI is scheduled to detect grade progression. An apparent rise in grade may reflect better sampling rather than true biological change.
After radiotherapy or hormone therapy
Treatment alters cell appearance. Conventional Gleason grading is not applied to such tissue, and reports should state this explicitly.
Men with chronic kidney disease or on dialysis
Antibiotic choice and dosing before biopsy, and contrast use for staging imaging, need adjustment. Tell every team involved about your kidney function.
Men with a strong family history or known BRCA2 variant
Grade interpretation is unchanged, but genetic counselling and germline testing may be advised, and it may affect surveillance for relatives and later treatment options.
The Gleason score in the Indian context
- Later-stage presentation is a recurring theme. Indian hospital series have repeatedly reported a higher proportion of high-grade and metastatic prostate cancer at first diagnosis than in countries with widespread PSA screening. A higher Gleason score at diagnosis therefore reflects presentation patterns as much as biology.
- Terminology: patients and clinics commonly say "prostate biopsy report", "PSA test" and "TRUS biopsy". The grade may be quoted as "3+4" without the Grade Group, ask for both.
- Antibiotic resistance has driven many Indian centres towards transperineal biopsy and towards culture-directed prophylaxis. Practice varies widely between hospitals.
- Uropathology expertise is concentrated in larger centres. If your biopsy was reported at a smaller laboratory and major surgery is planned, discuss slide review with your urologist. Blocks and slides can usually be retrieved and transported.
- Keep your slides and blocks traceable. Note the laboratory name and histopathology number; you will need them for any second opinion or for treatment at another hospital.
Cost and insurance in India
The Gleason score is not billed separately. The cost sits within the histopathology charge for the prostate biopsy specimen, which is in turn part of the biopsy procedure cost. Costs differ widely between government, trust and private hospitals and between cities, so ask for a written estimate before the procedure.
Factors that influence what you pay:
- Biopsy approach: transperineal biopsy under sedation or anaesthesia usually costs more than transrectal biopsy under local anaesthetic.
- MRI first: multiparametric MRI before biopsy adds a substantial separate cost.
- Number of cores and containers: histopathology is often priced per specimen container.
- Immunohistochemistry or special stains, added when the appearance is equivocal.
- Second opinion review of slides at a referral laboratory.
- Day-care versus inpatient admission, anaesthetist fees and operation theatre charges.
- Staging scans such as bone scan or PSMA PET-CT if the grade is high.
Insurance: diagnostic biopsy performed as day care or with admission is often covered under health insurance policies, but outpatient investigations frequently are not. Coverage depends on your policy terms, waiting periods and pre-existing disease clauses. Confirm with the hospital insurance desk and your insurer before the procedure. Government schemes including Ayushman Bharat PM-JAY cover cancer diagnosis and treatment packages at empanelled hospitals; eligibility and package details should be checked locally.
Myths and facts
| Myth | Fact |
|---|---|
| A Gleason score of 6 means moderate cancer | Gleason 6 is Grade Group 1, the lowest grade reported on biopsy. The scale in current use runs from 6 to 10. |
| A benign biopsy means no cancer | The biopsy describes the tissue sampled. Cancer elsewhere in the gland can be missed. Continued PSA follow-up is standard. |
| 3+4 and 4+3 are the same because both add to 7 | The order matters. 4+3 has more of the higher-grade pattern and generally carries greater risk. |
| Gleason 10 means nothing can be done | A high grade indicates aggressive disease, not a fixed outcome. Treatment options exist and outcomes vary by individual circumstances. |
| The Gleason score tells you if the cancer has spread | Grade describes cell appearance only. Spread is assessed by examination and imaging. |
| A higher PSA always means a higher Gleason score | PSA and grade are separate measures. High-grade cancers can occur with modest PSA values, and benign enlargement can raise PSA considerably. |
| The biopsy grade is final | Grade on the removed prostate may differ from the biopsy grade, and grade can be reassessed on repeat biopsy during surveillance. |
Frequently asked questions
Is there a normal Gleason score?
No. The Gleason score is assigned only when cancer is found in prostate tissue. A biopsy with no cancer has no Gleason score and is not "Gleason 0" or "Gleason 2". Older scores of 2 to 5 are no longer assigned to needle biopsies because those patterns proved unreliable and often represented benign tissue.
How long does it take to get the Gleason score after a biopsy?
The tissue needs fixing, processing, sectioning, staining and expert reading. Most units report within a few working days. Extra immunohistochemical stains, a difficult case, or referral of slides for specialist uropathology opinion will add time. Ask your urology team when your report is expected and how it will be communicated.
Can the Gleason score change?
The score for a given specimen does not change, but a later specimen can differ. Repeat biopsy during surveillance or examination of the removed prostate may show a higher or lower grade. This usually reflects better sampling of the gland rather than the cancer having transformed.
Should I get a second opinion on my biopsy slides?
It is reasonable, particularly when the grade sits at the boundary between Grade Group 1 and 2, when major surgery or radiotherapy is being planned, or when the report is equivocal. Slides and paraffin blocks can be retrieved from the original laboratory and sent for specialist uropathology review.
What is the difference between the Gleason score and the Grade Group?
Both describe the same tissue. The Gleason score is the sum of patterns, from 6 to 10. The Grade Group converts this into 1 to 5, separating 3+4 from 4+3, and avoids the misleading impression that 6 is mid-scale. Current reports should state both.
Does a Gleason 6 always need treatment?
Not necessarily. Many men with Grade Group 1 disease are offered active surveillance, with scheduled PSA testing, examination, MRI and repeat biopsy. The decision also weighs the number of positive cores, PSA level, MRI findings, age and personal preference. Discuss the options with your urologist rather than assuming either way.
Can an MRI give me a Gleason score without a biopsy?
No. MRI assigns a PI-RADS suspicion category and guides where to biopsy. Grading requires tissue examined under a microscope. MRI also cannot reliably exclude cancer; a negative MRI reduces but does not remove the possibility of clinically significant disease.
Why does my report mention cribriform or intraductal carcinoma?
These are specific architectural patterns recognised as adverse features. Their presence can influence whether active surveillance is offered and may prompt more intensive treatment or closer follow-up, even within the same Gleason score. Ask your urologist how these findings affect your particular plan.
How often will my Gleason score be rechecked?
There is no fixed interval. Men on active surveillance have repeat assessment on a schedule set by their team, typically combining PSA, examination, MRI and periodic repeat biopsy. Men who have had treatment are usually followed with PSA and imaging rather than repeat grading.
Sources
- WHO Classification of Tumours: Urinary and Male Genital Tumours, International Agency for Research on Cancer.
- International Society of Urological Pathology (ISUP) consensus conferences on Gleason grading of prostatic carcinoma, including the 2014 and 2019 consensus statements.
- Epstein JI et al., contemporary Gleason grading and the Grade Group system, published in American Journal of Surgical Pathology and European Urology.
- European Association of Urology Guidelines on Prostate Cancer.
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate Cancer.
- Indian Council of Medical Research - National Centre for Disease Informatics and Research, National Cancer Registry Programme reports.
- College of American Pathologists protocol for the examination of prostate needle biopsy and radical prostatectomy specimens.
